Drug intelligence / Profile preview

AVR-101

Development stage: Preclinical
Lead developer: Avalor Therapeutics
Modality: Antibody-Based Therapeutics
Administration: Intraarticular

Overview

AVR-101 is an investigational, long-acting, intra-articular biologic inhibitor of interleukin-1 beta (IL-1β) being developed by Avalor Therapeutics. It is designed to suppress root-cause inflammation in chronic inflammatory joint diseases. The therapeutic candidate is currently in preclinical/IND-enabling development, with initial clinical focus on osteoarthritis (OA), refractory gout (RG), and calcium pyrophosphate deposition (CPPD) disease.

Targets

IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on AVR-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVR-101.

Explore the full profile